Endeavor

The Power of CAR T in Solid Tumor Treatment

CAR T therapy involves a patient’s own T cells that have been genetically engineered to target a patient’s own specific cancer.

CAR T Therapy Safe for Older Patients

Moffitt’s closer look at clinical trial data could expand therapy’s use and effectiveness.

Nearly 40 Percent of CAR T Patients Remain in Remission

Many ZUMA-1 participants remain in remission and more than half of those treated remain alive.

New Study Shows CAR T-cell Therapy for Lymphoma Lives up to its Press

Seventeen cancer centers compare real world outcomes of diffuse large B cell lymphoma patients treated with Yescarta® to ZUMA-1 clinical trial data

Moffitt Honors CAR T Patient during Veterans Day Ceremony

Moffitt honored Floyd Cook, other veterans during the annual flag-raising ceremony.

The General’s Daughter

Jessica Schwarzkopf will carry on her father’s legacy by taking part in Moffitt Cancer Center’s annual Veteran’s Day celebration at 8:30 a.m. on Nov. 9.

CAR T Drives New Ovarian Cancer Research

The new genetically-modified CAR T-cells seek out and destroy cancer cells expressing an FSH receptor protein found on a large number of ovarian cancer cells.

Father’s Cancer Battle Inspires Son’s Research

Moffitt Physician Co-Led Pivotal Study of CAR-T Therapy

CAR T Provides Remission, Purpose for Moffitt Leukemia Patient

For CAR T treatment, T cells are removed from a patient’s blood and sent to a lab where the cells are genetically modified to better enable them to identify and attack cancer cells.